Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma

References

• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851–858.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179–213.
   PubMed Web of Science ®Google Scholar
• Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996;93:1493–1495.
   PubMed Web of Science ®Google Scholar
• Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806–1814.
   PubMed Web of Science ®Google Scholar
• Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266: 11947–11954.
   Google Scholar
• Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273: 30336–30343.
   Google Scholar
• Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535–1545.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029–1039.
   PubMed Web of Science ®Google Scholar
• de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989–991.
   PubMed Web of Science ®Google Scholar
• Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579–1586.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611
   PubMed Web of Science ®Google Scholar
• Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66–70.
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289–300.
   PubMed Web of Science ®Google Scholar
• Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222–3230.
   Google Scholar
• Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001;20:2768–2778.
   PubMed Web of Science ®Google Scholar
• Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748–753.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706–1716.
   PubMed Web of Science ®Google Scholar
• Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72–79.
   PubMed Web of Science ®Google Scholar
• Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005;17:611–616.
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L, et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000;96:3712–3718.
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006;47:998–1005.
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao RJ, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2007;88:38–47.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009;50:728–735.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. pp 322–334.
   Google Scholar
• Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15–27.
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197:677–683.
   PubMed Web of Science ®Google Scholar
• Citak EC, Oguz A, Karadeniz C, et al. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol Res Pract 2008;204:89–96.
   PubMed Web of Science ®Google Scholar
• Passam FH, Alexandrakis MG, Kafousi M, et al. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009;205:11–20.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
   Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol 2001;67:279–288.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy. Eur J Haematol 2002;68: 289–298.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2004;59:765–781.
   PubMed Web of Science ®Google Scholar
• Turley H, Scott PA, Watts VM, et al. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 1998;186:313–318.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 2005;19:894–900.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 2006;29:408–417.
   PubMed Web of Science ®Google Scholar
• Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011;117: 3889–3899.
   PubMed Web of Science ®Google Scholar
• Delli Carpini J, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010;13:43–58.
   PubMed Web of Science ®Google Scholar
• Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res 2007;9:216.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999; 79:965–970.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, et al. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996;56:45–53.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamato M, Nakamine H, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002;68:91–100.
   PubMed Web of Science ®Google Scholar
• Jørgensen JM, Sørensen FB, Bendix K, et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma 2009;50:1647–1660.
   PubMed Web of Science ®Google Scholar
• Paydas S, Seydaoglu G, Ergin M, et al. The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma 2009;50:366–373.
   PubMed Web of Science ®Google Scholar
• Kanzler H, Küppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495–505.
   PubMed Web of Science ®Google Scholar
• Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997;183:44–50.
   PubMed Web of Science ®Google Scholar
• Agarwal B, Naresh KN. Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease.J Pathol 2002; 197: 677–683. J Pathol 2003;201:334–335.
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Angus B, Miller S, et al. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 2006;47: 223–230.
   PubMed Web of Science ®Google Scholar
• Pavlopoulos PM, Konstantinidou AE, Agapitos E, et al. A morphometric study of neovascularization in colorectal carcinoma. Cancer 1998;83:2067–2075.
   PubMed Web of Science ®Google Scholar
• Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78:1379–1384.
   PubMed Web of Science ®Google Scholar
• Panico L, Roncono F, Lepore M, et al. Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma. Leuk Lymphoma 2013 Apr 11. [Epub ahead of print]
   Google Scholar
• Glimelius I, Edstrom A, Fischer M, et al. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 2005;19:2360–2362.
   PubMed Web of Science ®Google Scholar
• Tsutsui S, Yasuda K, Suzuki K, et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005;14: 425–431.
   PubMed Web of Science ®Google Scholar
• Lissbrant IF, Stattin P, Wikstrom P, et al. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000;17:445–451.
   PubMed Web of Science ®Google Scholar
• Mäkitie T, Summanen P, Tarkkanen A, et al. Tumor-infiltrating macrophages (CD68 (+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:1414–1421.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362: 875–885.
   PubMed Web of Science ®Google Scholar
• Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011;52: 1913–1919.
   PubMed Web of Science ®Google Scholar
• Deau B, Bachy E, Ribrag V, et al. Macrophage, mast cell and T lymphocyte inflitrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma 2013;54:41–45.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096–1103.
   PubMed Web of Science ®Google Scholar